Statement of Changes in Stockholders' Equity (deficit) (unaudited) - USD ($)	Series 1 Convertible Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2018		$ 2,558	$ 9,727,124	$ (4,952,443)	$ 4,777,239
Balance (in shares) at Dec. 31, 2018		2,558,419
Stock-based compensation - stock options			54,382		54,382
Stock-based compensation - restricted stock units			22,500		22,500
Net loss				(1,528,056)	(1,528,056)
Balance at Mar. 31, 2019		$ 2,558	9,804,006	(6,480,499)	3,326,065
Balance (in shares) at Mar. 31, 2019		2,558,419
Balance at Dec. 31, 2019		$ 2,628	10,651,073	(12,781,660)	(2,127,959)
Balance (in shares) at Dec. 31, 2019		2,627,533
Issuance of Series 1 Convertible Preferred Stock, net of offering costs	$ 4		25,318,702		25,318,706
Issuance of Series 1 Convertible Preferred Stock, net of offering costs (in shares)	3,879
Issuance of Common Stock in ArTara Private Placement, net of offering costs		$ 285	1,867,295		1,867,580
Issuance of Common Stock in ArTara Private Placement, net of offering costs (in shares)		284,875
Issuance of Common Stock in Proteon Private Placement, net of offering costs		$ 1,897	12,411,440		12,413,337
Issuance of Common Stock in Proteon Private Placement, net of offering costs (in shares)		1,896,888
Reverse business combination		$ 1,033	34,531,594		34,532,627
Reverse business combination (in shares)		1,033,907
Stock-based compensation - stock options			368,135		368,135
Stock-based compensation - restricted stock units			2,429,672		2,429,672
Net loss				(10,060,257)	(10,060,257)
Balance at Mar. 31, 2020	$ 4	$ 5,843	$ 87,577,911	$ (22,841,917)	$ 64,741,841
Balance (in shares) at Mar. 31, 2020	3,879	5,843,203